Eli Lilly said last night it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation ...

B 2026 tracking litigation highlights drugmaker mandates and legal challenges reshaping hospital drug pricing and compliance risks.

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

On July 31, the US Department of Health and Human Services’ (HHS) Health Resources and Services Administration (HRSA) announced the availability of a new pilot program altering how pharmaceutical ...

“When a program designed to deliver targeted assistance drives up system-wide costs, reform is no longer optional,” says health expert Sally Pipes. “It's necessary.” If a charity organization ...

Pending legislation to expand providers’ access to discounted drugs has sparked strong lobbying campaigns for and against the proposal.

Unexpected windfall or fragile safety net? Affluent communities or vulnerable poor? Welfare check or supplemental provider program? Making sense of the latest 340B program study published by the ...

The Government Accountability Office believes Congress should slash the financial incentives the government pays hospitals in the 340B drug program, it said in a new report, over concerns that ...

As the Trump administration prepares to force its Most Favored Nation price controls on drug makers, a major U.S. lobbying group is pushing for a change to drug discounts law that would necessitate a ...

Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under the False Claims Act (“FCA”). In a recent decision, Adventist Health System v ...